SCHEMBL6138847

SCHEMBL6138847

Cc1ccc(C=Cc2ccc([C@H](O)CCCCC(=O)NO)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 15/20 0.53
HDAC8 Q9BY41 11/20 0.53
HDAC6 Q9UBN7 11/20 0.52
HDAC2 Q92769 11/20 0.52
HDAC3 O15379 10/20 0.52
HDAC10 Q969S8 10/20 0.52
HDAC11 Q96DB2 10/20 0.52
HDAC4 P56524 9/20 0.52
HDAC7 Q8WUI4 9/20 0.52
HDAC9 Q9UKV0 9/20 0.52
HDAC5 Q9UQL6 9/20 0.52
NCOR2 Q9Y618 1/20 0.51
STAT3 P40763 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6139001 1.00 HDAC1 (0.53) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138841 1.00 HDAC1 (0.53) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6390150 0.93 HDAC1 (0.59) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138744 0.89 HDAC1 (0.56) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138729 0.89 HDAC1 (0.56) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138730 0.87 HDAC1 (0.61) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138725 0.87 HDAC1 (0.61) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138855 0.85 HDAC1 (0.50) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138936 0.85 HDAC1 (0.52) HDAC1HDAC8HDAC6HDAC2HDAC3
SCHEMBL6138979 0.85 HDAC1 (0.52) HDAC1HDAC8HDAC6HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP claimed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US claimed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP claimed
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP disclosed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US disclosed
US-6770644-B1 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient ONO PHARMACEUTICALS CO., LTD. (JP) 2004-08-03 US disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient HIF1AN, IL6, PYGM HDAC1 942/4885HDAC8 1134/4885HDAC6 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.